Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PI3K Inhibitors in Relapsed/Refractory Indolent T/NK-Cell Lymphomas
NCT06530550Phase 2Recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Aug 2024
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of linperlisib, duvelisib in T-cell lymphoma, natural killer cell lymphoma, T-cell large granular lymphocytic leukemia, NK-cell large granular lymphocytic leukemia (NK-LGLL), sponsored by Institute of Hematology and Blood Diseases Hospital. Started Aug 2024; status: recruiting.
02
Drugs
linperlisibduvelisib
03
Conditions
T-cell lymphomanatural killer cell lymphomaT-cell large granular lymphocytic leukemiaNK-cell large granular lymphocytic leukemia (NK-LGLL)
Beyond the preview
Go deeper on NCT06530550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06530550.